Dermatologic Adverse Events in Patients Receiving Duvelisib Single-Agent and Combination Therapies
Clinical Lymphoma Myeloma and LeukemiaViviane Liao +5 more
openaire +2 more sources
The Development of Novel Therapies for Chronic Lymphocytic Leukaemia in the Era of Targeted Drugs. [PDF]
J Clin MedRobak T +4 more
europepmc +1 more source
Clinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center. [PDF]
Adv HematolLin KH +11 more
europepmc +1 more source
DYNAMO Study Supports Duvelisib for Indolent Non-Hodgkin Lymphoma
Oncology Times, 2019 openaire +2 more sources
PI3K Inhibitors in Hematology: When One Door Closes…. [PDF]
Clin Cancer ResSkånland SS, Okkenhaug K, Davids MS.
europepmc +1 more source
Advances in the combination of CAR-T therapy with small-molecule reagents for hematologic malignancies. [PDF]
Front ImmunolYang B, Su Y, Wang C, Yu L.
europepmc +1 more source
Maintenance Therapy Post-Stem Cell Transplantation for Patients with T-Cell Lymphomas. [PDF]
Curr Hematol Malig RepBraunstein Z, Brammer JE.
europepmc +1 more source
PI3Kδ Pathway Dysregulation and Unique Features of Its Inhibition by Leniolisib in Activated PI3Kδ Syndrome and Beyond [PDF]
, 2023 Cant AJ +4 more
core
Comparative safety of novel targeted therapies in relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis. [PDF]
Ther Adv Med OncolMonica M, Reczek M, Kawalec P.
europepmc +1 more source